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Background: Apoptin, a nonstructural protein encoded by the VP3 gene of chicken anemia virus (CAV), has been
shown to not only induce apoptosis when introduced into the precursors of chicken thymocytes, but has been
found to specifically kill human cancer cells, tumor cell and transformed cells without affecting the proliferation of
normal cells. This tumor-specific apoptotic characteristic of the protein potentially may allow the development of a
protein drug that has applications in tumor therapy. However, several major problems, which include poor
expression and poor protein solubility, have hampered the production of apoptin in bacteria.
Results: Significantly increased expression of recombinant full-length apoptin that originated from chicken anemia
virus was demonstrated using an E. coli expression system. The CAV VP3 gene was fused with a synthetic sequence
containing a trans-acting activator of transcription (TAT) protein transduction domain (PTD). The resulting construct
was cloned into various different expression vectors and these were then expressed in various E. coli strains. The
expression of the TAT-Apoptin in E. coli was significantly increased when TAT-Apoptin was fused with GST-tag
rather than a His-tag. When the various rare amino acid codons of apoptin were optimized, the expression level of
the GST-TAT-Apoptinopt in E. coli BL21(DE3) was significantly further increased. The highest protein expression level
obtained was 8.33 g/L per liter of bacterial culture after induction with 0.1 mM IPTG for 4 h at 25 °C. Moreover,
approximately 90% of the expressed GST-TAT-Apoptinopt under these conditions was soluble. After purification by
GST affinity chromatography, the purified recombinant TAT-Apoptinopt protein was used to evaluate the
recombinant protein’s apoptotic activity on tumor cells. The results demonstrated that the E. coli-expressed GST-
TAT-apoptinopt showed apoptotic activity and was able to induce human premyelocytic leukemia HL-60 cells to
enter apoptosis.
Conclusions: On expression in E. coli, purified recombinant TAT-Apoptinopt that has been fused to a GST tag and
had its codons optimized, was found to have great potential. This protein may in the future allow the development
of a therapeutic protein that is able to specifically kill tumor cells.* Correspondence: TCTZEN@dragon.nchu.edu.tw; m098026@cjc.edu.tw
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Chicken anemia virus (CAV), is a non-enveloped virus
and the causative agent of chicken anemia disease. The
disease results in aplastic anemia, lymph organ atrophy
and immunosuppression in chickens [1-3]. The virus
transcribes and translates three viral proteins, VP1, VP2
and VP3, which are respectively encoded by ORF3,
ORF1 and ORF2 of the CAV genome. VP1 protein
(51 kDa) is the sole structural protein of CAV and is re-
sponsible for capsid assembly [4]. The VP2 protein
(30 kDa) is a nonstructural protein that possesses a
dual-specificity protein phosphatase (DSP) [5]. The VP3
protein (13 kDa), also called apoptin, is a strong inducer
of apoptosis in precursor chicken thymocytes and vari-
ous human transformed and tumor cell lines but not in
normal cells [6]. At present, the full anti-tumor mechan-
ism of apoptin remains unclear. However, it is worth
mentioning that apoptin-induced apoptosis in tumor
cells is p53-independent and also is not suppressed by
Bcl-2 or BCR-ABL protein [7]. Thus, apoptin is thought
to be a good candidate for use as a therapeutic protein
and has potential to be developed as a cancer treatment,
including those cancers that lack p53.
To develop apoptin as an anti-cancer drug, efficient
transduction tools such as recombinant virus and a re-
combinant plasmid within liposomes have been used to
deliver apoptin into tumor cells [8]. However, these
approaches have restrictions in terms of therapeutic ap-
plication including a size limitation of the genes that can
be delivered, insertional mutagenesis and transient ex-
pression [9-11]. Novel cell-penetrating peptides, such as
the trans-acting activator of transcription (TAT) protein
transduction domain (PTD), which consists of 11 amino
acid residues (aa 47-57, YGRKKRRQRRR) have therefore
been used as vectors for protein delivery [8,12]. With re-
spect to apoptin, previously studies have been demon-
strated that apoptin fused with a TAT peptide shows
apoptotic activity against tumor cells because the TAT
peptide’s delivery system is able to move apoptin into
cells [13,14].
Up to the present, a number of different expression
systems have been used to express apoptin, including E.
coli, baculovirus-insect cells and plant cells [15-18].
However, production of recombinant full-length apop-
tin/VP3 protein has generally been possible only in E.
coli [17]. Several production problems involving the ex-
pression efficiency and protein solubility of apoptin in E.
coli have been encountered [13,17,18]. Thus, there is a
need to overcome these difficulties in order to scale-up
production of full-length apoptin protein using an E. coli
expression system. If successful, this would not only
allow the efficient development of a therapeutic protein
that is able to actively kill cancer cells specifically but
the recombinant protein would also be potentially usefulwhen developing diagnostic kits for the clinical detection
of CAV infection [17].
It is clear that E. coli has a number of limitations and
disadvantages in terms of the production of apoptin pro-
tein. However, expression of apoptin protein in E. coli is
still an attractive alternative to the current production
system when assessed in terms of cost, time and oper-
ational considerations. In this study, the CAV VP3 gene
was fused to a synthetic gene containing the trans-acting
activator of transcription (TAT) protein transduction do-
main (PTD). This protein, named TAT-Apoptin, was
expressed using various different expression vectors in
order to evaluate TAT-Apoptin expression and produc-
tion by a number of different E. coli strains. Two expres-
sion vectors were used, one harboring a glutathione-S-
transferase (GST) tag and the other a 6xHis tag; these
were investigated to explore the effect of these fusion
tags on the expression of TAT-Apoptin in the various E.
coli strains. In addition, changes in codon usage for vari-
ous amino acids within the VP3 gene were also assessed
in terms of their effect on expression of TAT-Apoptinopt.
Rare codons for E. coli within the VP3 gene of the TAT-
Apoptin protein were optimized using prediction soft-
ware and the preferred codon usage changed to that of E.
coli. After this optimization, the expression levels of the
modified VP3 genes were examined in various E. coli
strains and the various production parameters for TAT-
Apoptinopt protein expression assessed. To the best of
our knowledge, the yield of E. coli expressed recombinant
TAT-Apoptinopt in this study after codon optimization of
the VP3 gene is the highest known to date.
Results
A GST fusion tag improves the expression of recombinant
TAT-Apoptin protein in E. coli
To develop apoptin protein as anti-tumor drug, a com-
posite cDNA of the CAV VP3 gene fused synthetic gene
of TAT peptide was used to create two distinct expres-
sion constructs of TAT-Apoptin (Figure 1A, a and b).
These constructs, pET-TAT-VP3 and pGEX-TAT-VP3,
were transformed into three different E. coli strains in
order to investigate the effect of the fusion tags on the
expression of TAT-Apoptin. The 6 ×His and GST tags
were fused with TAT-Apoptin at the N-terminus using
the expression vectors pET28a and pGEX-4 T-1, respect-
ively. The expression of these two TAT-Apoptin con-
structs in various E. coli strains was explored (Figure 2).
When E. coli BL21(DE3) was used, significant amounts
of full-length TAT-Apoptin protein were present in the
whole cell lysate after IPTG induction for 4 h with either
pET-TAT-VP3 or pGEX-TAT-VP3 (Figure 2B, SDS-
PAGE and Western-blotting). The 16 kDa His-TAT-
Apoptin and the 42 kDa GST-TAT-Apoptin were
detected using monoclonal anti-His antibody and anti-
Figure 1 Schematic diagram of the constructs used for TAT-Apoptin protein expression. (A) Schematic representation of the TAT-Apoptin
protein fused with different affinity tags together with the expression vectors used in this study. The designations of the TAT-Apoptin protein and
its expression vectors are indicated, (a), (b), (c) and (d). The constructs, (a) and (b), contain the full-length TAT-VP3 gene cloned into the vectors
pET28a and pGEX-4 T-1; these were used for expression of TAT-Apoptin protein with either a six-histidine (6 ×His) tag or a glutathione-s-
transferase (GST) tag at the N-terminus, respectively. Constructs (c) and (d) containing the TAT-VP3 gene that was codon-optimized; this was
derived from construct (b) by replacing rare codons without altering the amino acid sequence. The codon-optimized TAT-VP3gene, TAT-VP3opt,
was then cloned into pET28a and pGEX-4 T-1. (B) Sequence comparison between the TAT-VP3 gene and the TAT-VP3opt gene. The nucleotide
sequences were compared between the original TAT-VP3 gene (wild type TAT-VP3) and the sequence of codon-optimized TAT-VP3 gene (TAT-
VP3Opt) over the whole coding region. An asterisk (*) represents the fact that the aligned nucleotides are identical.
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ern-blot). Densitometric analysis of the blots showed
that total expressed GST-TAT-Apoptin protein, both sol-
uble and insoluble, from BL21(DE3) was approximately
19 fold greater than that of His-TAT-Apoptin produced
under identical conditions (Figure 3A and C). When
His-TAT-Apoptin and GST-TAT-Apoptin were induced
for between 1 and 4 h, the expression of both proteins
continued to increase significantly over the 2-4 h induc-
tion range (Figure 3A and C) with the highest amount of
His-TAT-Apoptin protein produced being 0.34 mg/ml at
4 h of IPTG induction. In contrast, the highest amount
of GST-TAT-Apoptin produced was 7.13 mg/ml at 4 h.
A similar pattern of expression was observed for the two
proteins in BL21(DE3)CodonPlus-RP and BL21(DE3)
pLysS strains (Figure 2). The highest amounts of GST-
TAT-Apoptin produced by BL21(DE3)CodonPlus-RP
and by BL21(DE3)pLysS were 2.43 and 1.15 mg/ml, re-
spectively, after 4 h of IPTG induction (Figure 3A and
C). The parallel results for His-TAT-Apoptin were 0.09
and 0.82 mg/ml, respectively (Figure 3A and C). Thus
the GST fusion tag improved protein expression signifi-
cantly and allowed large amounts of intact TAT-Apoptin
protein to be produced.VP3 gene encoding apoptin protein of CAV is rich in E.
coli rare codons
CAV VP3 gene that encodes the apoptin protein consists
of 121 amino acid codons. The rare codons for E. coliwithin the VP3 gene were pinpointed using the Gen-
Script Rare Codon Analysis Tool (http://www.genscript.
com/cgi-bin/tools/rare_codon_analysis). The deduced
amino acid sequence of apoptin was found to contain
15% basic amino acid residues such as arginine (R) and
lysine (K) (Figure 1B). Overall, approximately 21% rare
E. coli codons were present in the VP3 gene, including
arginine, leucine, isoleucine, proline, cysteine, threonine,
serine and glycine codons (Figure 1B). The presence of
these codons is one possible reason for the relatively
poor expression of apoptin in E. coli.Enhancement of recombinant TAT-Apoptin protein
expression in E. coli by optimizing the codon usage of the
VP3 gene
We have shown that expression of full-length TAT-
Apoptin in E. coli is improved by fusing a GST tag to
the N-terminus of the TAT-Apoptin protein. However,
adding a His tag to give His-TAT-Apoptin did not pro-
duce such a yield improvement even when the optimal
host strain BL21(DE3)pLysS is used (Figures 2A and
3A). Therefore, we next explored the effect on TAT-
Apoptin productivity of optimizing the codon usage of
the VP3 gene for E. coli. The TAT-Apoptin gene was
engineered such that AGA/CGA/CGG were changed to
CGT or CGC (R), CCC/CCT were changed to CCG or
CCA (P), CTC/CTA/TTG were changed to CTG (L),
ATA was changed to ATC (I), GGA/GGG were chan-
ged to GGT (G), ACT/ACA were changed to ACC (T),
Figure 2 Expression of recombinant TAT-Apoptin protein in three different E. coli strains. The TAT-Apoptin protein expression in three E.
coli strains, BL21(DE3), BL21(DE3)pLysS and BL21(DE3)CodonPlus-RP, which were transformed with either pET-TAT-VP3 or pGEX-TAT-VP3 and
cultivated at 37 °C. His-TAT-Apoptin and GST-TAT-Apoptin protein were examined and detected using SDS-PAGE (A, C) and Western-blotting (B,
D). Anti-His and anti-GST tag monoclonal antibodies was respectively used to recognize the His-TAT-Apoptin protein and GST-TAT-Apoptin. Lane
M, pre-stained protein marker; the symbols “-” and “+” represented pre-induction and post-induction with 1 mM of IPTG over 4 hrs of cultivation
in E. coli, respectively.
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codon optimized VP3 gene was then linked to the TAT
sequence at 5’ end of the VP3 gene to give an intact
open reading frame. The new codon-optimized TAT-
VP3 gene, denoted TAT-VP3opt, was then cloned into
pGEX-4 T-1 and pET28a to give pGEX-TAT-VP3opt
and pET-TAT-VP3opt, respectively (Figure 1A, d and c).
These plasmids were then individually expressed in E.
coli. When expression in E. coli strain BL21(DE3) using
whole cell lysate was analyzed by SDS-PAGE and
Western blotting, both GST-TAT-Apoptinopt and His-
TAT-Apoptinopt were successfully expressed after IPTG
induction (Figure 4A and C) with a yield after 4 h
IPTG induction of about 9 mg/ml and 0.65 mg/ml, re-
spectively. The yield of GST-TAT-Apoptinopt was al-
most 13 fold higher than His-TAT-Apoptinopt
(0.65 mg/ ml) (Figure 5A and C). BL21(DE3)-pLysS,similarly, gave increased expression of both His- TAT-
Apoptinopt and GST-TAT-Apoptinopt (Figure 4A and
C). The highest yields of GST-TAT-Apoptinopt and His-
TAT-Apoptinopt in BL21(DE3)pLysS were obtained after
4 h IPTG induction and were 6.38 and 1.2 mg/ml, re-
spectively (Figure 5A and C). These results confirm
that the codon-optimized of TAT-Apoptin improved
protein expression significantly and allowed large
amounts of intact TAT-Apoptinopt protein to be pro-
duced in either E. coli BL21(DE3) or BL21(DE3)pLysS
with either fusion tag.
Effect of cultivation temperature and IPTG concentration
on the protein solubility of E. coli-expressed GST-TAT-
Apoptinopt
In addition to the expression level of TAT-Apoptinopt,
the solubility of TAT-Apoptinopt protein is also needs to
Figure 3 Productivities of TAT-Apoptin protein and the growth curves of the three recombinant E. coli strains. The productivities of His-
TAT-Apoptin (A) and GST-TAT-Apoptin (C) for the three E. coli strains, BL21(DE3), BL21(DE3)pLysS, and BL21(DE3)CodonPlus-RP containing pET-
TAT-VP3 or pGEX-TAT-VP3 are shown over the time course of cultivation at 37 °C after IPTG induction. The growth curves of BL21(DE3), BL21(DE3)
CodonPlus-RP and BL21(DE3)pLysS expressing His-TAT-Apoptin (B) and GST-TAT-Apoptin (D), respectively, in LB medium post-induction.
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parameters and their effect on the TAT-Apoptinopt pro-
tein solubility were explored, namely cultivation
temperature and the IPTG concentration for induction;
GST-TAT-Apoptinopt was used as the model protein.
Protein solubility and the expression levels of GST-TAT-
Apoptinopt were determined using E. coli BL21 (DE3) at
25 °C and 37 °C. As shown in Figure 6A, an increased
amount of soluble GST-TAT-Apoptinopt was obtained
after IPTG induction at 25 °C. Approximately 15% and
65% of the GST-TAT-Apoptinopt in the whole cell lysate
of the BL21(DE3) strain was soluble at 37 °C and 25 °C,
respectively. In addition, the amounts of GST-TAT-
Apoptinopt protein expressed in BL21(DE3) were
8.33 mg/ml and 8.99 mg/ml, respectively, at 25 °C and
37 °C after 4 h IPTG induction (Figures 5C and 7A);
thus the total amount of GST-TAT-Apoptinopt protein
obtained at 25 °C compared to 37 °C was only very
slightly lower (Figures 5C and 7A).
When various IPTG induction concentration from 0.1
to 1 mM were explored for protein induction, the high-
est amount of GST-TAT-Apoptinopt protein obtained
was with 1 mM IPTG induction using the BL21(DE3)
strain (Figure 6B) and this gave about 65% soluble pro-
tein at 25 °C (Figure 6C). The expression level of GST-TAT-Apoptinopt at 0.1 and 0.5 mM IPTG was lower than
for 1 mM IPTG (Figure 6B), but the amount of soluble
protein was highest at 0.1 mM (95%) IPTG (Figure 6C).
Thus a lower cultivation temperature of 25 °C and an
IPTG concentration of 0.1 mM IPTG were able to pro-
duce the higher amount of soluble GST-TAT-Apoptinopt
protein.
Purification of recombinant GST-TAT-Apoptinopt protein
using GST affinity chromatography
Using the approximately 95% soluble GST-TAT-Apopti-
nopt expressed by E. coli at 25 °C and 0.1 mM IPTG, the
lysate was subjected to purification using a GST affinity
column. After affinity chromatography, the eluted sol-
uble GST-TAT-Apoptinopt protein was confirmed antige-
nically using anti-GST antibody and CAV-infected
positive serum (Figure 8A, B and C). A typical elution
profile of the protein fractions collected from a GST col-
umn is shown in Figure 8A after separation by SDS-
PAGE. Fraction 4 contains the most eluted protein, has
a significant absorbent peak at OD280 and was eluted at
12 min (data not shown). The specific 42 kDa band
eluted in fraction 4 was almost purified to homogenicity
(Figure 8A, lane 4 of elution). When the purified GST-
TAT-Apoptinopt protein was examined by MALDI-TOF,
Figure 4 Expression of recombinant TAT-Apoptinopt protein in the different E. coli strains. The TAT-Apoptinopt protein was expressed in
the E. coli strains BL21(DE3) and BL21(DE3)pLysS, which contained either pET-TAT-VP3opt or pGEX-TAT-VP3opt, at 37 °C. His-TAT-Apoptinopt and
GST-TAT-Apoptinopt protein were examined and detected using SDS-PAGE (A, C) and Western-blotting (B, D). Anti-His and anti-GST tag
monoclonal antibodies was respectively used to recognize the His-TAT-Apoptinopt protein and GST-TAT-Apoptinopt. Lane M, pre-stained protein
marker; “-” and “+” represented pre-induction and post-induction with 1 mM of IPTG over 4 hrs of cultivation in E. coli, respectively.
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tified after trypsin digestion and these demonstrated
good alignment and a high score when compared to the
predicted protein (data not shown). The longest peptide
fragment, VNELKESLITTTPSRPR, consists of 17 amino
acid residues and overall the coverage was 35.7% of the
published amino acid sequence of apoptin (Accession
No. AF212490) without any miss-match (Figure 8D).
These MALDI-TOF results confirmed that the purified
42 kDa protein is GST-TAT-Apoptinopt and that the
E. coli preferred codon usage optimization within the
VP3 gene has not altered either the amino acid sequence
(Figure 8C; Figure 8B, lane 4) or the antigenicity
(Figure 8C) of the protein.Recombinant GST-TAT-Apoptinopt protein has apoptotic
activity and induces apoptosis in HL-60
To investigate whether GST-TAT-Apoptinopt protein
expressed by E. coli has apoptotic activity when intro-
duced into tumor cells, purified GST-TAT-Apoptinopt
protein was used to examine the protein's apoptotic ac-
tivity when it was used to treat human premyelocytic
leukemia HL-60 cells. As illustrated in Figure 9, flow
cytometry analysis by Annexin-V FITC and propidium
iodide staining showed an approximately 10% increase
in the level of apoptotic levels among HL-60 cells that
were co-cultured with GST-TAT-Apoptinopt compared
to HL-60 cells only, HL-60 co-cultured with GST or
chromatographic elution buffer. However, compared to
Figure 5 Productivities of TAT-Apoptinopt protein and the growth curves of two recombinant E. coli strains. The productivities of His-TAT-
Apoptinopt (A) and GST-TAT-Apoptinopt (C) using two E. coli strains, BL21(DE3) and BL21(DE3)pLysS containing either pET-TAT-VP3opt or pGEX-TAT-
VP3opt, respectively, are shown over a time course after IPTG induction at 37 °C. The growth curves of BL21(DE3) and BL21(DE3)pLysS expressing
His-TAT-Apoptinopt (B) and GST-TAT-Apoptinopt (D) in LB medium post-induction.
Lee et al. BMC Biotechnology 2012, 12:27 Page 7 of 14
http://www.biomedcentral.com/1472-6750/12/27the control, HL-60 cells co-cultured with GST-TAT-
Apoptinopt induced less apoptosis than when HL-60 cells
were induced into apoptosis by treatment with cyclohex-
amide (CHX). Nevertheless, GST-TAT-Apoptinopt was
able to induce apoptosis in HL-60 cells to a meaningful
degree. These results indicate that E.coli expressed GST-
TAT-Apoptinopt retains the protein’s original apoptotic
activity when used to treated HL-60 cells even after the
modifications carried out in this study.
Discussion
Apoptin from chicken anemia virus has been demon-
strated to have apoptotic activity and to be able to spe-
cifically kill several types of tumor cells including the
cell lines HeLa, Saos-2, lung cancer cells H1299 and
HepG2 [9-11,13,14,19]. Apoptin is not only p53 and Bcl-
independent, but also does not require specific post-
modification in order to be able to induce apoptosis [7].
Therefore, apoptin has great potential to be developed
into a protein drug that will be useful as part of the can-
cer therapy armory. In this context, previously studies
have shown that fusing the TAT peptide to apoptin, in
order to create a recombinant protein vehicle, which
allows protein uptake by cells, improves protein trans-
location into the cell and increases Saos-2 cell killing[19]. This approach is a useful was of overcoming pro-
blems associated with the delivery of apoptin into cells
without affecting the anti-cancer activity of the protein.
However, up to the present, few studies have investi-
gated anti-cancer activity using such a recombinant
TAT-Apoptin protein. The main reason for this lack of
progress is the poor expression and low protein solubil-
ity of TAT-Apoptin. Previous studies have shown that
the large-scale production of recombinant TAT-Apoptin
using a prokaryotic expression is difficult and therefore
this has become a bottle-neck [17,18]. Even today, in
spite of the fact that many eukaryotic expression systems
are well established, various factors, such as cost-effect-
iveness, insertional mutagenesis and transient expres-
sion, still need to be resolved for these systems. Taking
the above into consideration, the effective production of
TAT-Apoptin protein using a prokaryotic system is a
crucial key step in developing this protein drug as an
anti-tumor therapy. Therefore, in this study, the specific
aim was to develop a prokaryotic expression system that
allowed the efficient production of recombinant TAT-
Apoptin protein. Using a prokaryotic expression system
to express heterologous recombinant protein has several
advantages including time-savings, cost-effectiveness,
ease of production, simplified characterization and
Figure 6 Solubility of E. coli-expressed GST-TAT-Apoptinopt
protein under using various cultivation parameters during
protein induction. The solubility of GST-TAT-Apoptinopt was
determined in the BL21(DE3) strain at different cultivation
temperatures (A) and in the presence of various concentrations of
IPTG (B, C).
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used expression system when evaluating the expression
of a foreign protein [20]. Indeed, the above points are
some of the critical factors associated with choosing a
suitable production system when developing a proteindrug. To this end, problems associated with having a
truly effective system for the large-scale production of
apoptin protein still needed to be explored.
To improve protein expression and to enhance the
solubility of any protein produced in an E. coli expres-
sion system, a number of strategies are available. These
include cultivation parameters, the effect of fusing the
protein to an affinity tag and the optimization of codon
usage of foreign gene for E. coli. All of these have been
frequently employed to improve the amount of recom-
binant protein recovered [17,18,21-23]. In the present
study, we first explored the effect of two different fusion
tags on TAT-Apoptin expression, although others re-
main available, are untested as yet and may further im-
prove the yield in the future. The presence of a GST
fusion tag was found to significantly improve the yield of
TAT-Apoptin compared to a 6 ×His tag (Figures 2 and
3). In a previous study, Liu et al successfully overcame
the problem of less efficient expression in E. coli of por-
cine circovirus (PCV) by fusing the maltose-binding pro-
tein (MBP) to an 8xHis tag [23]. The main mechanism
by which the MBP-8xHis tag improved protein expres-
sion remains unclear. However, one possibility is
improved protein solubility [24]. Similarly, in our previ-
ous study, the addition of a GST tag to the CAV VP1
protein also improved expression in E. coli significantly
compared to a His × 6 tag [21]. Thus it would seem that
some fusion tags are able to improve expression of sol-
uble protein in E. coli compared to other tags, perhaps
by aiding the correct folding of their fused partner
[21,24].
Next we investigated which of three different E. coli
strains, BL21(DE3), BL21(DE3)pLysS and BL21(DE3)
Codonplus-RP, was able to improve protein production
and yield. With both GST-TAT-Apoptin and His-TAT-
Apoptin, BL21(DE3) was preferred and produced more
TAT-Apoptin protein than either BL21(DE3)pLysS or
BL21(DE3)Codonplus-RP (Figure 2A and C). It is worth
noting that BL21(DE3)pLysS has a higher growth rate
than BL21(DE3) or BL21(DE3)Codonplus-RP when
expressing His-TAT-Apoptin (Figure 2B and D). This dis-
crepancy may involve either poor protein stability or the
cytotoxic nature of His-TAT-Apoptin when present in
BL21(DE3) and BL21(DE3)Codonplus-RP. These results
are similar to those obtained for the production of GST-
VP1 protein from CAV in E. coli at low expression levels
[21]. BL21(DE3)pLysS superiority may be due to the pres-
ence in the strain of the pLysS plasmid during protein in-
duction [17,21]. This difference may enable BL21(DE3)
pLysS to tolerate cytotoxicity associated with the expres-
sion of T7 lysozyme by attenuating the transcription leak-
age by T7 RNA polymerase [17,21]. However, this
phenomenon was not important when GST-TAT-Apoptin
was expressed and the growth profiles of the three strains
Figure 8 Purification of recombinant GST-TAT-Apoptinopt protein. SDS-PAGE(A) and Western-blot (B) analysis of the GST-TAT-Apoptinopt
protein contained in various elution fractions collected from the GSTrap FF affinity column. The cytosolic extract of E. coli strain BL21(DE3)
expressing GST-TAT-Apoptinopt protein was loaded onto a GSTrap FF column and the bound protein was eluted with elution buffer as described
in Material and Methods. The eluted protein from the GSTrap FF affinity column was analyzed by SDS-PAGE and Western blotting using
monoclonal anti-GST antibody. (C) Antigenicity analysis of GST-TAT-Apoptinopt. The purified GST-TAT-Apoptinopt was assayed by Western blotting
using positive CAV-infected chicken serum. Lane M, pre-stained protein marker; lane 1, flow through; lane 2, fraction obtained after column
washing, lane 3 and 4, eluted fraction 1 and 2, respectively, collecting after column elution.(D) Identity of the GST-opt-VP1 protein determined by
MALDI-TOF. The bold letters represent actual amino acid matches to published amino acid sequence (Accession No. AF212490).
Figure 7 Productivities of TAT-Apoptinopt protein and the growth curves in two recombinant E. coli strains. The productivities of GST-
TAT-Apoptinopt using two E. coli strains, BL21(DE3) and BL21(DE3)pLysS containing pGEX-TAT-VP3opt are shown over time after IPTG induction at
25 °C (A). Growth curves of BL21(DE3) and BL21(DE3)pLysS expressing GST-TAT-Apoptinopt, respectively, in LB medium post-induction (B).
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Figure 9 Induction of apoptosis in HL-60 cells by GST-TAT-Apoptinopt. An apoptotic assay of HL-60 cells was performed by flow cytometry
after 90 ug/ml of the purified E. coli-expressed recombinant GST-TAT-Apoptinopt protein was co-cultured with HL-60 cell for 24 hours (D). Non-
apoptosis controls, (A), (B) and (C), were assayed. These represent respectively HL-60 cells only, HL-60 cells co-cultured with protein buffer and
HL-60 cells co-cultured with GST protein. The apoptosis induced by CHX was used as a positive apoptosis control.
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http://www.biomedcentral.com/1472-6750/12/27producing GST-TAT-Apoptin were almost identical on in-
duction by IPTG. In this area, it is possible that the
cytotoxicity of GST-TAT-Apoptin may be less that that of
His-TAT-Apoptin in BL21(DE3) and BL21(DE3)Codon-
plus-RP [21]. Furthermore, the phenomenon of “protein
burden” may not have been encountered when BL21(DE3)
was used to express GST-TAT-Apoptin [25]. It was con-
cluded that BL21(DE3) is the preferred choice for expres-
sion of GST-TAT-Apoptin.
Rosenberg et al have proposed that the abundance of
a rare codon near the 5’-end of the gene might affect the
efficiency of protein translation [26]. If this is true, then
the approach used in the present study to modify the
codon usage in the gene ought to improve the expres-
sion of full-length apoptin protein. When Genscript
OptimumGeneTM bioinformatic software was used to
identify rare codons in E. coli that exist in the wild-type
CAV VP3 gene, the pinpointed amino acid residues
included arginine, leucine, proline and lysine; these are
commonly found in the N-terminus and C-terminus
regions of the apoptin protein. After codon optimization
of CAV VP3 gene, TAT-Apoptinopt was fused with both
tags and successful expressed in E. coli (Figure 4A, C).
The amount of expressed GST-TAT-Apoptinopt in E. coli
was substantially higher than that of GST-TAT-Apoptin
and His-TAT-Apoptinopt when BL21(DE3) or BL21(DE3)
pLysS were used (Figure 5A, C and Table 1). Thus codon
optimization within VP3 gene of the rare codons in E.
coli was able to improve the expression level of TAT-
Apoptin; specifically translation efficiency was improved
without the need to supply extra copies of the rare tRNA
genes [27,28]. Interestingly, in terms of growth, BL21
(DE3) and BL21(DE3)pLysS performed almost identically
when expressing GST-TAT-Apoptin (Figure 3D). How-
ever, the growth rate of BL21(DE3)pLysS was signifi-
cantly slower than that of BL21(DE3) when expressing
GST-TAT-Apoptinopt (Figure 5D). This might be
explained in terms of the “protein burden” within BL21
(DE3)pLysS when it is producing GST-TAT-Apoptinopt
at a relatively high level early during induction and this
protein burden may eventually result in BL21(DE3)pLysS
undergoing growth arrest. The growth profile of BL21Table 1 Summary of the productivities of the various TAT-Ap




His-TAT-Apoptinopt 0.65± 0.06 1.20±0
GST-TAT-Apoptinopt
a 8.99± 0.65 6.38±0
GST-TAT-Apoptinopt
b 8.33± 0.89 7.84±0
a E. coli Strains were cultured at 37 °C.
b E. coli Strains were cultured at 25 °C.(DE3) expressing GST-TAT-Apoptinopt may involve the
balancing of the steady-state growth conditions for the
strain with the yield and also suggests that this strain
had reached the maximum possible growth rate; as a re-
sult the growth profile of BL21(DE3) during the expres-
sion of GST-TAT-Apoptinopt did not significantly change
(Table 1, Figures 3D and 5D). In contrast, when produ-
cing His-TAT-Apoptinopt, the growth profiles of BL21
(DE3) and BL21(DE3)pLysS were very similar to the
situation when the strains were producing His-TAT-
Apoptin (Figures 3B and 5B). One possible explanation
for this is that the level of produced His-TAT-Apoptin
or His-TAT-Apoptinopt did not reach the threshold value
where there was a protein burden and therefore no
growth arrest occurred.
The presence of a fusion tag and optimization of the
codon usage within the gene were both useful strategies
for improving the production of TAT-Apoptin (Table 1).
When compared, the increase level in yield obtained
when a fusion tag was used seems to be greater than
that derived from codon optimization (Table 1). Specific-
ally, the yield was only increased from 7.1 mg/ml (GST-
TAT-Apoptin) to 8.9 mg/ml (GST-TAT-Apoptinopt) was
expressed in BL21(DE3).
In order to improve the protein stability of TAT-Apop-
tin, various cultivation parameters were adjusted. Al-
though a cultivation temperature of 37 °C was able to
produce a higher growth rate and greater protein yield,
this temperature did not produce a high yield of soluble
protein. When 25 °C was used or when a lower IPTG
concentration was used (0.1 mM of IPTG), it was not
only possible to obtain a similar expression level of
TAT-Apoptin within 6 hrs (compared to 4 hrs), but
there was also a significant improvement in protein solu-
bility (Figures 6A, 7A). Recovering soluble TAT-Apoptin
using the GST tag as an affinity ligand during the purifi-
cation process is highly convenient in terms of down-
stream processing. After GST affinity chromatography,
approximately 80% of the GST-TAT-Apoptin produced
by the E. coli was recovered and recovery of GST-TAT-
Apoptin even reached over 90% with one batch
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a protein drug with high purity.
In this study, human premyelocytic leukemia HL-60
cells were used to evaluate the apoptotic activity of the
E. coli-expressed TAT-Apoptin. Apoptosis was induced
when the HL-60 cells were co-cultured with 90 ug/ml of
GST column purified GST-TAT-Apoptinopt. There was a
10% increase in apoptosis compared to the non-apop-
tosis control (Figure 9A, B and C). However, this is less
apoptosis than that induced by CHX, which is the posi-
tive apoptosis control. Previous studies have reported
that approximately 70% of tumor cells undergoing apop-
tosis in the presence of apoptin [11]. This discrepancy
may be a result of differences in the tumor cell lines
used, which may have different levels of tolerance with
respect to apoptin. In addition, the TAT-Apoptin carried
the GST fusion tag had not undergo protease cleavage
before use and the presence of the tag may have affected
the protein drug's apoptotic activity during co-culture
with the tumor cells. Nevertheless, it is clear that the E.
coli-expressed GST-TAT-Apoptinopt produced in the
present study does retain its anti-tumor cell activity and
the ability to induce apoptosis.Conclusions
The expression of recombinant full-length TAT-Apoptin
protein was established successfully herein using a pro-
karyotic system, and the yield was significantly improved
by fusing the protein with an affinity tag and by optimiz-
ing the codon usage of the polypeptide for expression in
E. coli. Direct engineering of the apoptin protein was a
convenient and cost-effective strategy of increasing the
expression of TAT-Apoptin protein in E. coli. This paves
the way for the large-scale production of TAT-Apoptin
protein using this approach. In the future, this will also
allow TAT-Apoptin to be used for the development of a
protein drug that has anti-cancer activity or as part of a
CAV diagnostic test.Methods
Bacterial strain and cells inoculation
Three E. coli strains, BL21(DE3) (Invitrogen, Carlsbad,
CA), BL21(DE3)CodonPlus-RP (Stratagene, La Jolla,
CA) and BL21(DE3)pLysS (Stratagene, La Jolla, CA)
were used and maintained at 37 °C using 10 ml Luria-
Bertani (LB)medium (1% tryptone, 0.5% yeast extract,
1% NaCl, pH 7.0) in 50 ml flasks. For strain activation,
0.5 ml of an overnight culture were inoculated into
50 ml LB medium and grown at 37 °C for around 3 h,
by which time the optical density of culture had reach
0.5 of OD600. These bacterial cells could then be used
for transformation or for protein expression.Construction of the recombinant plasmids
A 420 bp of synthetic cDNA encoding the full-length
CAV apoptin protein that was fused to a trans-acting ac-
tivator of transcription (TAT) protein transduction do-
main (PTD) at its N-terminus, the latter being
synthesized by Genemark Biosci & Tech Co. (Taichung,
Taiwan) and then ligated into pBluescript II SK(−) using
Bam H1 (Takara, Japan) and Xho I (Takara, Japan) re-
striction sites. The resulting recombinant plasmid was
designated pB-TAT-VP3. The TAT-VP3 gene then was
subcloned into either pET28a (Novagen, Madison, WI)
or pGEX-4 T-1 (GE Healthcare, Piscataway, NJ) using
Bam H1 and Xho I. The resulting constructs were desig-
nated pET-TAT-VP3 and pGEX-TAT-VP3 (Figure 1A, a
and b), respectively. To generate the VP3 gene of CAV
harboring the codon optimized nucleotide sequence, a
codon optimized fragment of VP3 gene fused with the
TAT PDT was also synthesized by Genemark Biosci &
Tech Co. and then ligated into the pBluescript II SK(−)
using Bam H1 and Xho I restriction sites. The TAT-
VP3opt gene was then further subcloned into either
pET28a or pGEX-4 T-1 as described above and the
resulting constructs were designated pET-TAT-VP3 opt
and pGEX-TAT-VP3opt, respectively (Figure 1A, c and
d). The constructs described above were then trans-
formed into One ShotW Top10 (Invitrogen, CA) chem-
ically competent E. coli for maintenance of the
recombinant plasmids and for protein expression. Trans-
formants that contained a gene of the correct size by
PCR were then confirmed as correct by restriction en-
zyme digestion and by DNA sequence analysis.
Expression of TAT-Apoptin protein and codon optimized
TAT-Apoptinopt protein in recombinant E. coli
To express the His-TAT-Apoptin, GST-TAT-Apoptin,
His-TAT-Apoptinopt and GST-TAT-Apoptinopt proteins,
the four constructed recombinant plasmids, pET-TAT-
VP3, pGEX-TAT-Apoptin, pET-TAT-VP3opt and pGEX-
TAT-VP3opt, were transformed into E. coli strain to
allow evaluation of protein expression. Three E. coli host
strains, BL21(DE3), BL21(DE3)CodonPlus-RP and BL21
(DE3)pLysS, each being a different recombinant con-
structions, were used for protein induction and expres-
sion. The recombinant strains were grown in LB
medium in the presence of kanamycin (50 μg/ml), ampi-
cillin (50 μg/ml) or chloramphenicol (34 μg/ml) as ap-
propriate at 37 °C. When the culture had reached an
optical density (OD600) of 0.5, isopropyl-β-D-thiogalac-
topyronoside (IPTG) at different concentrations was
added to induce protein expression and then growth was
continued for 4 h. After IPTG induction, samples of the
cells were harvested and analyzed for protein expression.
Protein concentration was determined using the proced-
ure described in a previous study [21]. Samples
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Apoptin or His-TAT-Apoptinopt and GST-TAT-Apoptin
or GST-TAT-Apoptinopt, were analyzed by 12.5% SDS-
PAGE and Western-blotting using a monoclonal anti-
His antibody (Invitrogen, Carlsbad, CA) or a monoclonal
anti-GST antibody (GE healthcare, Piscataway, NJ).
Purification of recombinant GST-TAT-Apoptinopt protein
using GST affinity chromatography
To purify the recombinant GST-TAT-Apoptinopt pro-
teins, cells were spun down from 50 mL of culture
supernatant and resuspended in GST resin binding buf-
fer (140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4,
1.8 mM KH2PO4, pH 7.3). The mixture was then soni-
cated on ice three times for 3 minutes with a 20% pulsed
activity cycle (MISONIX SonicatorW 300). Next, the lys-
ate was centrifuged for 10 min at 10,000 rpm to remove
the cell debris. The resulting cell supernatant was loaded
onto a GSTrap FF affinity column (GE healthcare, Pis-
cataway, NJ) for protein purification using the standard
procedure described in a previous study [21]. The total
protein concentration of each collected fraction from
the column was determined using a Micro BCA kit
(Pierce, Rockford, IL) with bovine serum albumin acting
as the reference protein. The purity of the protein from
each fraction was analyzed by 12.5% SDS-PAGE and
then the resulting gels were Western blotted using
monoclonal anti-GST antibody (GE healthcare, Piscat-
away, NJ).
Mass spectrometry
To confirm the identity of the recombinant apoptin pro-
tein, E. coli expressed GST-TAT-Apoptin was purified by
GSTrap FF column, and then the eluted proteins con-
taining in collected fraction were separated by 12.5%
SDS-PAGE. The relevant band was then cut out from the
12.5% SDS-PAGE gel after Coomassie blue staining and
digested with trypsin. The resulting samples were sub-
jected to the MALDI-TOF-MS mass spectrometry (ESI-
QUAD-TOF) to allow amino acid sequence identification
of the protein, as described in a previous study [17].
Apoptosis assay
Human promyelocytic leukemia HL-60 cells (CCRC
60043) were purchased from the Food Industry Research
and Development Institute (FIRDI) (Hsichu. Taiwan).
These cells were used to evaluate the apoptotic activity
of GST-TAT-Apoptinopt using an Annexin-V FITC apop-
tosis kit (BD Phaemingen, San Diego, CA). The cell was
grown in the FIRDI-suggested medium, and all experi-
ments were performed in 6-well culture plates. The cul-
tured HL-60 cells were stained with Annexin-V FITC
and propidium iodide (PI) according to manufacturer’s
guidelines. Briefly, 2 × 105 cells were co-cultured with 90ug/ml of GST-TAT-Apoptinopt for 24 hrs, and then
resuspended in 100 ul of 1× binding buffer, which was
followed by incubation with 2.5 ul of Annexin-V FITC
and PI at room temperature for 30 min. Finally the cells
were added to 200 ul of 1× binding buffer and assayed
immediately using FACSCanto flow cytometry (BD Bios-
ciences, San Jose, CA). A positive control was included
and this consisted of treating the cells with 100 mM
cycloheximide (CHX) (Sigma-Aldrich, USA) for 24 hrs.
The negative controls were either cells treated with pro-
tein buffer (50 mM Tris-HCl, 10 mM reduced glutathi-
one, pH 8.0) or cells treated with 90 ug/ml glutathione-
S-transferase (GST) protein for 24 hrs.
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